UA113875C2 - Спосіб лікування стероїдзалежних дерматозів - Google Patents

Спосіб лікування стероїдзалежних дерматозів

Info

Publication number
UA113875C2
UA113875C2 UAA201412609A UAA201412609A UA113875C2 UA 113875 C2 UA113875 C2 UA 113875C2 UA A201412609 A UAA201412609 A UA A201412609A UA A201412609 A UAA201412609 A UA A201412609A UA 113875 C2 UA113875 C2 UA 113875C2
Authority
UA
Ukraine
Prior art keywords
methyl
chloro
pyrazol
mammal
ethyl
Prior art date
Application number
UAA201412609A
Other languages
English (en)
Inventor
Панкаж Агарвал
Вінод Кумар
Цин Се
Original Assignee
Новартіс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48143295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA113875(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартіс Аг filed Critical Новартіс Аг
Publication of UA113875C2 publication Critical patent/UA113875C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Винахід належить до галузі медицини і стосується способу лікування стероїд-залежних дерматозів у ссавців, що потребують цього, який включає введення терапевтично ефективної кількості сполуки, вибираної з N-{(1S)-2-aміно-1-[(3-фторфеніл)метил]етил}-5-хлор-4-(4-хлор-1-метил-1Н-піразол-5-іл)-2-тіофенкарбоксаміду або його фармацевтично прийнятної солі та N-{(1S)-2-аміно-1-[(3,4-дифторфеніл)метил]етил}-5-хлор-4-(4-хлор-1-метил-1Н-піразол-5-іл)-2-фуранкарбоксаміду або його фармацевтично прийнятної солі.
UAA201412609A 2012-04-24 2013-04-22 Спосіб лікування стероїдзалежних дерматозів UA113875C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261637390P 2012-04-24 2012-04-24
US201361782565P 2013-03-14 2013-03-14
PCT/EP2013/058249 WO2013160222A1 (en) 2012-04-24 2013-04-22 Treatment method for steroid responsive dermatoses

Publications (1)

Publication Number Publication Date
UA113875C2 true UA113875C2 (uk) 2017-03-27

Family

ID=48143295

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201412609A UA113875C2 (uk) 2012-04-24 2013-04-22 Спосіб лікування стероїдзалежних дерматозів

Country Status (26)

Country Link
US (2) US20150087683A1 (uk)
EP (1) EP2841053A1 (uk)
JP (1) JP2015514792A (uk)
KR (1) KR20150010943A (uk)
CN (1) CN104302275A (uk)
AR (1) AR090795A1 (uk)
AU (1) AU2013254849B2 (uk)
BR (1) BR112014026706A2 (uk)
CA (1) CA2873751A1 (uk)
CL (1) CL2014002861A1 (uk)
CO (1) CO7111283A2 (uk)
CR (1) CR20140491A (uk)
DO (1) DOP2014000238A (uk)
EA (1) EA201491914A1 (uk)
HK (1) HK1201726A1 (uk)
IL (1) IL235159A0 (uk)
MX (1) MX2014012904A (uk)
NZ (1) NZ628394A (uk)
PE (1) PE20142356A1 (uk)
PH (1) PH12014502400A1 (uk)
SG (1) SG11201406409VA (uk)
TW (1) TW201347758A (uk)
UA (1) UA113875C2 (uk)
UY (1) UY34762A (uk)
WO (1) WO2013160222A1 (uk)
ZA (1) ZA201407345B (uk)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821299A (zh) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 噻吩衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002734A1 (en) * 2004-07-01 2006-01-12 Unilever N.V. Moisture barrier
CA2578384A1 (en) * 2004-09-06 2006-03-16 Altana Pharma Ag Novel pyrazolopyrimidines
CA2602197A1 (en) * 2005-04-12 2006-10-19 Merck & Co., Inc. Inhibitors of akt activity
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP4242206A1 (en) * 2009-01-30 2023-09-13 Novartis AG Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
EA022982B1 (ru) * 2009-10-08 2016-04-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Комбинация для лечения рака или предраковых синдромов
WO2011146710A1 (en) * 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination

Also Published As

Publication number Publication date
WO2013160222A1 (en) 2013-10-31
CL2014002861A1 (es) 2015-01-16
SG11201406409VA (en) 2014-11-27
DOP2014000238A (es) 2014-12-15
ZA201407345B (en) 2015-11-25
CN104302275A (zh) 2015-01-21
UY34762A (es) 2013-11-29
EP2841053A1 (en) 2015-03-04
NZ628394A (en) 2016-02-26
AU2013254849B2 (en) 2016-05-26
AU2013254849A1 (en) 2014-11-06
BR112014026706A2 (pt) 2017-06-27
CR20140491A (es) 2014-12-22
CO7111283A2 (es) 2014-11-10
US20160143885A1 (en) 2016-05-26
CA2873751A1 (en) 2013-10-31
TW201347758A (zh) 2013-12-01
PE20142356A1 (es) 2015-01-30
KR20150010943A (ko) 2015-01-29
JP2015514792A (ja) 2015-05-21
HK1201726A1 (en) 2015-09-11
IL235159A0 (en) 2014-12-31
AR090795A1 (es) 2014-12-10
MX2014012904A (es) 2014-11-21
EA201491914A1 (ru) 2015-01-30
US20150087683A1 (en) 2015-03-26
PH12014502400A1 (en) 2015-01-12

Similar Documents

Publication Publication Date Title
PH12014502324A1 (en) Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
PH12014502040A1 (en) Heterocyclyl compounds
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
IN2014MN02106A (uk)
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
CA2920410C (en) Thienopiperidine derivative and use thereof
SG10201900504XA (en) Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
MX2013008074A (es) Combinacion.
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2014002395A (es) Inhibidores de rock suaves, novedosos.
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона
NZ708526A (en) Novel rock inhibitors
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
UA113875C2 (uk) Спосіб лікування стероїдзалежних дерматозів
MX2016004267A (es) Combinacion.
WO2015031198A3 (en) Bendamustine pharmaceutical compositions
MX2014011843A (es) Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
IN2015DN03909A (uk)
MA20150066A1 (fr) Procédé pour le traitement de dermatoses répondant aux stéroïdes